Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab for conversion therapy in RAS/BRAF wild-type right-sided colon cancer with initially unresectable liver-only metastases
ChiCTR2000037711Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cetuximab, bevacizumab, fluorouracil, folinic acid, oxaliplatin and 1 more in colon cancer and colorectal cancer (CRC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: conversion-to-resection rate. Started Oct 2020; status: recruiting.
02
Drugs
cetuximabbevacizumabfluorouracilfolinic acidoxaliplatin
03
Conditions
colon cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2000037711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037711.